Study of the Consequences of Mutations of the RNU4ATAC and RTTN Genes by Transcriptomic, Biochemical and Cellular Approaches in Order to Determine the Pathophysiology of Their Associated Syndromes: Microcephalic Osteodysplastic Primordial Dwarfism Type I/III, Roifman Syndrome and Lowry-Wood Syndrome

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

In the human genome, about 750 genes contain one intron excised by the minor spliceosome. These genes are named U12 genes, and these introns, minor or U12 introns. The minor spliceosome comprises its own set of snRNAs, among which U4atac. Its non-coding gene, RNU4ATAC, has been found mutated in Taybi-Linder (TALS), Roifman (RFMN) and Lowry-Wood syndromes (LWS). These rare developmental disorders associate ante- and post-natal growth retardation, microcephaly, skeletal dysplasia, intellectual disability, retinal dystrophy and immunodeficiency. Their physiopathological mechanisms remain unsolved: the number of U12 genes involved, their identity and function, or the cellular mechanisms impacted by the splicing defect, are still unknown. The hypothesis of the study is that U12 genes coding for primary cilia components are particularly sensitive to minor splicing defects caused by RNU4ATAC mutations. Indeed, a child showing signs of TALS but negative for RNU4ATAC was found to carry a homozygous variant in the RTTN gene, coding for the rotatin protein located at the centrosome and the base of the primary cilia and playing a role in maintaining these structures. In addition, bi-allelic RNU4ATAC mutations were identified in five patients presenting with traits suggestive of the Joubert syndrome (JBTS), a well-characterized ciliopathy. These patients also present with traits typical of TALS/RFMN/LWS. To better understand the causes of these pathologies, a cohort of patients with syndromes associated with bi-allele mutations of the RNU4ATAC or RTTN gene will be gathered, in order to conduct studies on the cells of these patients. Blood samples will be taken, as well as skin biopsies, if possible. These samples will be used to create induced pluripotent stem cell lines. Blood samples will also be collected from the parents of RNU4ATAC patients, to eliminate in transcriptomic analyses expression variations due to differences in genetic background. Biopsies of skin, muscle and brain tissue will be collected on foetuses carrying two-allele RNU4ATAC or RTTN mutations whose parents have had a miscarriage or have chosen to have a medical abortion. The biological samples collected will be used to study the transcription level of U12 genes, the splicing of their pre-messenger RNA, their main cellular functions, and the structural characteristics of tissues and cells.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

⁃ TALS, RFMN, LWS or other pathology patients

• Woman or man

• All ages

• Presence of bi-allelic mutations of RNU4ATAC or RTTN

• Written consent of parents or legal guardian(s)

• Affiliation to a Social Security scheme

⁃ Healthy participants (Parent of the patient)

• Woman or man

• Major

• Presence of mono-allelic mutations of RNU4ATAC

• Written consent of the participant

• Affiliation to a Social Security scheme

⁃ Parents having recourse to a medical termination of pregnancy or having had a spontaneous miscarriage (for fetus samples)

• Woman or man

• Major

• Presence of bi-allelic mutations of RNU4ATAC or RTTN in the fetus

• Written parental consent

• Affiliation to a Social Security scheme

Locations
Other Locations
France
Centre de référence des anomalies du développement et syndromes malformatifs du Sud-Ouest Occitanie Réunion, CHU de Bordeaux-GH Pellegrin
NOT_YET_RECRUITING
Bordeaux
Centre de référence anomalies du développement de Lyon, Hôpital Femme Mère Enfant
RECRUITING
Bron
Centre de référence des anomalies du développement et syndromes malformatifs de l'Est, CHU de DIJON
NOT_YET_RECRUITING
Dijon
Centre de référence des anomalies du développement et syndromes malformatifs de l'inter région Nord-Ouest, Hôpital J de Flandre
NOT_YET_RECRUITING
Lille
Unité Fonctionelle d'embryo-fœtopathologie, Hôpital Necker-Enfants Malades
NOT_YET_RECRUITING
Paris
Centre de référence des anomalies du développement et syndromes malformatifs de l'Ouest, Hôpital Sud
NOT_YET_RECRUITING
Rennes
Contact Information
Primary
Sylvie MAZOYER, Dr
sylvie.mazoyer@inserm.fr
04 81 10 65 33
Backup
Patrick EDERY, Pr
charles-patrick.edery@chu-lyon.fr
04 72 12 96 98
Time Frame
Start Date: 2024-08-27
Estimated Completion Date: 2029-08-27
Participants
Target number of participants: 45
Treatments
Other: RNU4ATAC patient
Patient with bi-allelic mutation of the RNU4ATAC gene
Other: RNU4ATAC fetus
Fetus with bi-allelic mutation of the RNU4ATAC gene
Other: RNU4ATAC parent
Parent of patient or fetus with bi-allelic mutation of the RNU4ATAC gene and who present themselve mono-allelic mutation of the RNU4ATAC gene
Other: RTTN patient
Patient with bi-allelic mutation of the RTTN gene
Other: RTTN fetus
Fetus with bi-allelic mutation of the RTTN gene
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.